6-chloro-3-(1H-imidazol-5-yl)-4-phenyl-1H-quinolin-2-one | 835881-91-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-chloro-3-(1H-imidazol-5-yl)-4-phenyl-1H-quinolin-2-one
• CAS: 835881-91-9
• 化学式: C₁₈H₁₂ClN₃O
• 分子量: 321.766
• InChiKey: HEOZOQPSOOSDNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,6-dichloro-3-(1H-imidazol-5-yl)-4-phenylquinoline 在 乙酸铵 、 溶剂黄146 作用下， 生成 6-chloro-3-(1H-imidazol-5-yl)-4-phenyl-1H-quinolin-2-one
  参考文献：
  名称：

  Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors

  摘要：

  A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.088

文献信息

• Quinolinone derivatives as inhibitors of c-fms kinase
  申请人：Wall J. Mark

  公开号：US20050049274A1

  公开（公告）日：2005-03-03

  The invention is directed to compounds of Formulae I and II: wherein R 1 , R 2 , R 3 , R 5 , R 6 , Y 1 , Y 2 , Y 3 , Y 4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  本发明涉及公式I和II的化合物：其中R1、R2、R3、R5、R6、Y1、Y2、Y3、Y4和X如规范中所示，以及其溶剂化物、水合物、互变异构体或药学上可接受的盐，它们能够抑制蛋白酪氨酸激酶，特别是c-fms激酶。
• IDO Inhibitors
  申请人：Mautino Mario R.

  公开号：US20110136796A1

  公开（公告）日：2011-06-09

  Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R 1 , R 4 , and R 5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine -2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供了按照公式(I)或(II)定义的化合物以及含有这些化合物的药物组合物，其中R1、R4和R5的定义在此处。这些化合物和组合物对于调节吲哚胺2,3-二氧化酶的活性；治疗吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制；治疗从抑制吲哚胺-2,3-二氧化酶的酶活性中获益的医疗状况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制具有用处。
• QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1660087A2

  公开（公告）日：2006-05-31
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2291187A2

  公开（公告）日：2011-03-09
• US7326788B2
  申请人：——

  公开号：US7326788B2

  公开（公告）日：2008-02-05